ArticleBMC ophthalmology2025
Clinical features and recurrence patterns of pediatric idiopathic orbital inflammatory disease.
Article in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Idiopathic Orbital Inflammation Masquerading as Relapse of Seronegative Juvenile Myasthenia Gravis: A Case Report.Journal of paediatrics and child health · 2026Article
- Orbital Myositis in Pediatric and Adult Patients: A Comparative Case Report and Review of the Literature.Cureus · 2026Article
- Painful acute esotropia as a presenting sign of presumed post-infectious orbital myositis in a child: a case report.BMC ophthalmology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundIdiopathic orbital inflammatory disease (IOID) is a non-specific orbital inflammatory condition that is uncommon in children. Due to limited data and the unique characteristics of the developing immune system in children, this study examined the clinical features, imaging subtypes, treatment outcomes, and recurrence patterns.
methodsPediatric patients (≤ 18 years) diagnosed with IOID at Beijing Tongren Hospital, Capital University between January 2020 and January 2025 were included in this retrospective review. Clinical data, imaging characteristics, treatment regimens, and recurrence patterns were collected. Cases were further classified into six anatomical subtypes based on orbital imaging.
resultsA total of 10 patients (12 eyes) were included, with a mean age of 9.9 ± 3.2 years. Imaging subtypes included diffuse (5, 50%), posterior scleritis (3, 30%), dacryoadenitis (1, 10%), and orbital apex involvement (1, 10%). Clinical symptoms were conjunctival injection (9, 90%), optic disc edema (8, 80%), decreased visual acuity (8, 80%), eyelid swelling (7, 70%), periorbital pain (6, 60%), ocular pain (4, 40%), and ptosis (4, 40%). Orbital MRI revealed posterior scleral and/or Tenon's capsule thickening with enhancement (8, 80%), optic nerve or sheath enhancement (5, 50%), lacrimal gland enlargement (4, 40%), and cavernous sinus thickening or dural enhancement (2, 20%). All patients received systemic corticosteroids, with a mean follow-up duration of 17.9 ± 12.5 months. Nine patients experienced recurrence, with seven of them related to steroid dependence in diffuse-type cases. Final visual acuity was ≥ 0.3logMAR in all relapsed cases.
conclusionPediatric IOID frequently presents with diffuse or deep orbital involvement on imaging. While corticosteroid therapy is generally effective, these subtypes may be more prone to steroid-dependent relapse during tapering. The association between steroid tapering and relapse remains to be fully substantiated, and further studies are needed to explore this potential relationship. Imaging-based classification may help predict recurrence risk and guide individualized long-term management strategies for pediatric IOID.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.